Sarepta TherapeuticsSRPT

那斯達克 · USD
16.71
+0.48
(+2.96%)
收盤 03/07 04:59 (UTC+8)
盤後 
17.49 
+0.78 
(+4.67%)
03/07 04:59 (UTC+8)

財務數據

損益表

loading
載入中...
icon
  • 3.32
  • 3.97
  • 4.13
  • 3.63
  • 4.67
  • 6.58
  • 7.45
  • 6.11
  • 3.99
  • 4.43
icon
  • 27.02
  • 19.58
  • 4.20
  • -12.22
  • 28.72
  • 40.94
  • 13.13
  • -17.96
  • -34.65
  • 10.91
  • icon
    營業收入(億)
  • icon
    季增長率(%)
單位:美元千元
年季
2025/Q4
2025/Q3
2025/Q2
2025/Q1
2024/Q4
2024/Q3
2024/Q2
2024/Q1
2023/Q4
2023/Q3
營業收入淨額
442,934
399,356
611,091
744,856
658,412
467,172
362,931
413,464
396,781
331,817
營業成本
398,708150,775152,558137,564132,30491,69144,54550,55944,17637,026
營業毛利
44,226
248,581
458,533
607,292
526,108
375,481
318,386
362,905
352,605
294,791
營業費用
455,809351,970342,956907,678364,427353,285319,087-327,980315,633
研發費用
325,336218,890204,392773,448199,953224,483179,690200,396195,517194,301
推銷及管理費用
128,29791,893137,897133,629163,873128,200138,796127,003131,700120,893
非經常性項目費用
1,49940,510--------
其他營業費用
677677667601601602601601763439
營業利益
-410,084
-103,389
115,577
-300,386
161,681
22,196
-701
34,905
24,625
-20,842
其他收入及費用
133,287-90,66038,061-83,13210,06211,81014,2786,54315,746-12,332
利息費用
----------
稅前純益
-278,296
-194,049
153,638
-383,518
171,743
34,006
13,577
41,448
40,371
-33,174
所得稅
4,551-14,102-43,25463,99012,6943957,1175,329-5,2847,763
稅後純益
-282,847
-179,947
196,892
-447,508
159,049
33,611
6,460
36,119
45,655
-40,937
基本每股稅後盈餘(元)
-2.74-1.802.01-4.601.650.350.070.38--0.46
稀釋每股稅後盈餘(元)
-2.76-1.802.03-4.601.560.340.070.370.76-0.45
基本平均股數(千股)
104876.00100237.0098005.0097362.0096283.0095390.0094618.0093991.00-88889.00
稀釋平均股數(千股)
96258.00100237.00106623.0097362.00108474.00100448.0099144.0099114.00-88889.00
還原基本每股稅後盈餘(元)
-2.74-1.802.01-4.601.650.350.070.38--0.46
還原稀釋每股稅後盈餘(元)
-2.76-1.802.03-4.601.560.340.070.370.76-0.45
還原基本平均股數(千股)
104,876100,23798,00597,36296,28395,39094,61893,991-88,889
還原稀釋平均股數(千股)
96,258100,237106,62397,362108,474100,44899,14499,114-88,889
EBITDA(千元)
-273,423-176,732162,612-375,452175,39533,19711,83837,79138,414-34,848

大家都在看

HOT